Sun Pharmaceutical Industries Limited (BOM:524715)
India · Delayed Price · Currency is INR | Market Cap | 4.56T +16.5% |
| Revenue (ttm) | 599.11B +11.4% |
| Net Income | 120.96B +16.6% |
| EPS | 50.40 +16.5% |
| Shares Out | n/a |
| PE Ratio | 37.74 |
| Forward PE | 33.43 |
| Dividend | 16.00 (0.84%) |
| Ex-Dividend Date | Jul 7, 2026 |
| Volume | 29,107 |
| Open | 1,919.50 |
| Previous Close | 1,901.00 |
| Day's Range | 1,883.45 - 1,919.50 |
| 52-Week Range | 1,547.25 - 2,047.55 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 2,167.21 (+14.01%) |
| Earnings Date | Jul 31, 2026 |
About BOM:524715
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations, and active pharmaceutical ingredients (APIs) in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including neuropsychiatry, cardiology, diabetes, gastroenterology, pain/analgesics, gynecology, ophthalmology, urology, dermatology, respiratory, anti-infectives, oncology, psychiatry, neurology, orthopaedic, nephrology, dental, and nutritionals. It ... [Read more]
Financial Performance
In fiscal year 2026, BOM:524715's revenue was 584.62 billion, an increase of 11.19% compared to the previous year's 525.78 billion. Earnings were 114.79 billion, an increase of 5.04%.
Financial StatementsAnalyst Summary
According to 34 analysts, the average rating for 524715 stock is "Buy." The 12-month stock price target is ₹2,167, which is an increase of 14.01% from the latest price.
News
Sun Pharma withdraws 11 eye medicines
India News: NEW DELHI: Eleven ophthalmic products marketed by Sun Pharma have been withdrawn after the company's distribution arm directed retailers to stop furth.
Sun Pharmaceutical Industries Transcript: Q1 26/27
Q1 FY 2027 saw 10.1% revenue growth, led by India and innovative medicines, while U.S. generics declined. Organon acquisition is on track, and Sun maintains high single-digit growth guidance for the year. Gross margin improved to 80.5% on a better product mix.
Sun Pharmaceutical Industries Quarterly report: Q1 2027
Sun Pharmaceutical Industries has published its Q1 2027 quarterly earnings report on July 31, 2026.
Sun Pharma's quarterly profit jumps on strength in specialty medicines
India's Sun Pharmaceutical Industries reported a 27% rise in first-quarter profit on Friday, driven by robust growth in its high-margin specialty medicines business as the country's largest drugmaker ...
Earnings To Watch: Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q1 2027 -- GF Value Sees ...
Earnings To Watch: Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q1 2027 -- GF Value Sees 10% Upside
Madras HC refuses to quash FIR in counterfeit medicines case
Madras HC refuses to quash FIR against Puducherry pharma firms accused of making counterfeit Sun Pharma drugs; orders CBI to file final report in 12 weeks.
India's Sun Pharma wins South Africa approval to launch generic Ozempic
India's Sun Pharmaceutical Industries has received approval from South Africa's health regulator to manufacture and sell a generic version of semaglutide, the active ingredient in Novo Nordisk's top-s...
Pharma sector stocks today, July 2: Alembic Pharma falls 1.88%, Glenmark Pharma jumps 0.91%, Sun Pharma gains 0.67%
Indian pharma stocks showed mixed performance in early trading on July 2, 2026. The BSE Healthcare index rose 0.24% to 49,237.19, while the broader market also posted gains with the…
Sun Pharma to acquire Innovcare Lifesciences for $28.7 million
Sun Pharmaceutical Industries on Saturday said it will acquire 100% of Innovcare Lifesciences in a deal valued at about 2.71 billion rupees ($28.73 million).
Sun Pharmaceutical to acquire Innovcare Lifesciences for Rs 271.2 crore
Sun Pharmaceutical Industries has announced its agreement to acquire 100% of the outstanding shares of Innovcare Lifesciences Private Limited, a Mumbai-based company. Innovcare is engaged in the marke...
Brokerage calls today, June 17: Sun Pharma, Polycab, AU SFB, Navin Fluorine, Coforge, PB Fintech in focus
Several brokerage firms have reiterated their ratings and revised target prices for major Indian stocks on June 17, highlighting growth prospects, business outlook, and sector trends across pharmaceut...
Macquarie reiterates ‘Outperform’ on Sun Pharma, maintains target price of Rs 2,150
Brokerage firm Macquarie has reaffirmed its ‘Outperform’ rating on Sun Pharmaceutical Industries Ltd. and retained its target price of Rs 2,150, while maintaining a positive stance on the proposed Sun...
Sun Pharmaceutical Industries reports arrest of independent director Gautam Doshi
Sun Pharmaceutical Industries has announced the arrest of its independent director, Mr. Gautam Doshi. The company clarified that the matter is unrelated to its operations and is not expected to…
Sun Pharmaceutical sets Rs 5 per share final dividend with July 7 record date
Sun Pharmaceutical Industries has announced that its 34th Annual General Meeting (AGM) will be held on Friday, 31 July 2026, at 4:00 p.m. IST through video conferencing. The company will…
Nifty 50 top gainers in morning trades today, June 8: Apollo Hospitals up 1.0%, SBI gains 0.8%, Sun Pharma rises 0.6%
Nifty 50 stocks saw muted gains during the morning session on June 8, 2026, with only a handful of stocks posting positive moves. The top gainers list was led by…
Sun Pharmaceutical Industries Slides: Investor presentation
Sun Pharmaceutical Industries has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
Sun Pharma share price target: Brokerages remain positive on specialty growth and strong India business
Shares of Sun Pharmaceutical Industries remained in focus on Tuesday, May 27, with brokerages continuing to maintain a constructive outlook on the pharmaceutical major, driven by its specialty busines...
Sun Pharma To Present Long-Term Follow-up Data On UNLOXCYT
(RTTNews) - Sun Pharmaceutical Industries Limited (SUNPHARMA) said it will share updated results from the locally advanced cutaneous squamous cell carcinoma expansion cohort from the CK-301-101 trial ...
Pharma Sector Stocks Today, May 25: Torrent Pharma up 4.23%, Glenmark Pharma gains 4%, Sun Pharma down 0.31%
The pharmaceutical sector showed mixed performance on May 25, 2026, during the early morning trade. The broader market remained positive with the Nifty 50 rising 0.92% to 23,937.85 as of…
Sun Pharmaceutical Industries Transcript: Q4 25/26
Q4 FY 2026 saw 13.6% sales growth and strong gross margins, but EBITDA margin declined due to higher costs and lower milestone income. Innovative medicines and India business drove growth, while U.S. generics faced competition. Organon acquisition and new launches support future outlook.
Sun Pharmaceutical Industries Quarterly report: Q4 2026
Sun Pharmaceutical Industries has published its Q4 2026 quarterly earnings report on May 22, 2026.
Sun Pharmaceutical Industries Annual report: Q4 2026
Sun Pharmaceutical Industries has published its Q4 2026 annual report on May 22, 2026.
Sun Pharma Q4 Results: Net profit rises 26.2% YoY, EBITDA grows over 6%
Sun Pharmaceutical Industries Ltd reported a strong set of Q4FY26 results, driven by healthy growth in its innovative medicines portfolio and steady expansion across global markets. For the quarter en...
Top Q4 results today, May 22: Sun Pharma, Hindalco Industries, Eicher Motors, Torrent Pharma, NTPC Green among key companies to announce earnings
A fresh set of companies is scheduled to announce their financial results for the quarter and financial year ended March 2026 on Friday, May 22. Key earnings announcements today include…
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q4 2026 Earnings Report Preview: What to Expect
Sun Pharmaceuticals Industries Ltd (NSE:SUNPHARMA) Q4 2026 Earnings Report Preview: What to Expect